Acta Haematol

1. XIE B, Li F, Xue W, Zhang Q, et al
   Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia.
   Acta Haematol. 2026 Oct 10:1. doi: 10.1159.
   

   >> Share

   
   
2. KASNER MT, Courtenay-Luck N, DiNardo C, Post SM, et al
   Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study.
   Acta Haematol. 2026;149:553-563.
   

   >> Share

   
   

   
   Am J Hematol

3. 
   Abstracts from the Lymphoma, Leukemia & Myeloma Congress October 13-16, 2026.
   Am J Hematol. 2026;101 Suppl 4:3-66.
   

   >> Share

   
   
4. ROMERO RIQUELME MA, Aspas Requena G, Lloret-Madrid P, Gil C, et al
   Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.
   Am J Hematol. 2026;101:2812-2826.
   

   >> Share

   
   
5. AVENOSO D, Farina M, Malagola M, Chalandon Y, et al
   Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.
   Am J Hematol. 2026;101:2736-2745.
   

   >> Share

   
   

   
   Ann Hematol

6. CHOI DH, Jung CW, Jang JH
   Donor-source-specific competing risks of relapse and non-relapse mortality in adult B-ALL allogeneic hematopoietic stem cell transplantation on a rabbit antithymocyte globulin-based platform.
   Ann Hematol. 2026;105:460.
   

   >> Share

   
   
7. STRZALKA K, Strzalka P, Jarych D, Wisnik A, et al
   Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker.
   Ann Hematol. 2026;105:452.
   

   >> Share

   
   

   
   Blood

8. RODRIGUEZ-ARBOLI E, Soria-Saldise E, Barragan E, Ayala R, et al
   Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.
   Blood. 2026 Oct 16:blood.2026033409. doi: 10.1182/blood.2026033409.
   

   >> Share

   
   
9. RUBIO-GAYARRE A, Vinyoles M, Tejedor JR, Guerrero-Murillo M, et al
   The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.
   Blood. 2026;148:2013-2028.
   

   >> Share

   
   

   
   Br J Haematol

10. GAO J, Qiu H, Tong Y, Huang C, et al
    Venetoclax-enhanced reduced-intensity conditioning in older patients aged >/=55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.
    Br J Haematol. 2026;209:1773-1782.
    

    >> Share

    
    
11. TIZRO P, Aldoss I, Wang X, Kwak LW, et al
    B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
    Br J Haematol. 2026;209:1530-1537.
    

    >> Share

    
    
12. MURAYAMA E, Kawai T, Yamato G, Shiba N, et al
    Multiomics analysis focusing on genome-wide DNA methylation in paediatric acute promyelocytic leukaemia.
    Br J Haematol. 2026;209:1586-1597.
    

    >> Share

    
    
13. LIU R, Li B, Zhang J, Xu W, et al
    Multiparameter flow cytometry versus droplet digital polymerase chain reaction for monitoring measurable residual disease in paediatric fusion gene-positive acute myeloid leukaemia.
    Br J Haematol. 2026;209:1562-1573.
    

    >> Share

    
    
14. PALMIERI R, Piciocchi A, Soddu S, Frigeni M, et al
    Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
    Br J Haematol. 2026;209:1735-1745.
    

    >> Share

    
    
15. KUNADT D, Zukunft S, Rollig C, Metzelder S, et al
    Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
    Br J Haematol. 2026;209:1783-1796.
    

    >> Share

    
    
16. KISLOVA M, Dmitrieva E, Naumova E, Pochtar M, et al
    Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.
    Br J Haematol. 2026;209:1664-1672.
    

    >> Share

    
    

    
    Eur J Haematol

17. ASLAN M, Yilmaz E
    Interpreting the Association Between Plasma Citrulline and Bloodstream Infection in Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Oct 13. doi: 10.1111/ejh.70341.
    

    >> Share

    
    

    
    Gene

18. HE L, Zhao C, Lu P, Zhao X, et al
    Aberrant splicing caused by a homozygous AK2 c.498?+?1G?>?A variant in a patient with reticular dysgenesis and concurrent B-cell acute lymphoblastic leukemia.
    Gene. 2026 Oct 14:150439. doi: 10.1016/j.gene.2026.150439.
    

    >> Share

    
    

    
    J Immunol

19. NIGAM N, Matsukawa T, Bertoli R, Tremblay ML, et al
    Ptpn1 deficiency collaborates with a NUP98::HOXD13 fusion gene to generate B cell precursor acute lymphoblastic leukemia.
    J Immunol. 2026;215:vkag250.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

20. CHENG C, Tong C, Jiang L, Wang Y, et al
    Incidence and Predictors of Symptomatic Thrombosis During Asparaginase-containing Therapy in Children With Acute Lymphoblastic Leukemia: A Meta-analysis and Narrative Synthesis.
    J Pediatr Hematol Oncol. 2026 Oct 13. doi: 10.1097/MPH.0000000000003307.
    

    >> Share

    
    

    
    J Virol

21. BANGHAM CRM, Matsuoka M
    Primer: Human T-cell leukemia virus type 1 (HTLV-1).
    J Virol. 2026 Oct 14:e0118326. doi: 10.1128/jvi.01183.
    

    >> Share

    
    

    
    Leuk Lymphoma

22. KANNAN S, Jennings J, Hutchinson L, Higgins A, et al
    Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.
    Leuk Lymphoma. 2026 Oct 15:1-6. doi: 10.1080/10428194.2026.2747547.
    

    >> Share

    
    

    
    Leuk Res

23. GINOSYAN AA, Ashouri K, Vu A, Grove S, et al
    Pediatric-inspired USC-ALL regimen vs hyper-CVAD in adults with Ph-negative and Ph-like acute lymphoblastic leukemia.
    Leuk Res. 2026;171:108344.
    

    >> Share

    
    
24. BALI JS, Chauhan R, Suresh SP, Murugan S, et al
    NGS-based retrospective profiling of BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Findings from the largest South Asian cohort.
    Leuk Res. 2026;171:108341.
    

    >> Share

    
    
25. ASGHAR Z, Saeed N, Shaikh MU
    Intensive induction chemotherapy in adult acute myeloid leukemia: A single centre assessment of complete remission and induction mortality.
    Leuk Res. 2026;171:108340.
    

    >> Share

    
    

    
    Leukemia

26. VAZQUEZ R, Sajot M, Nasrallah J, Birsen R, et al
    Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.
    Leukemia. 2026 Oct 13. doi: 10.1038/s41375-026-03160.
    

    >> Share

    
    

    
    N Engl J Med

27. CHIARETTI S, Piciocchi A, Skert C, Leoncin M, et al
    Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
    N Engl J Med. 2026;395:1483-1494.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share